Delivering enzymes to defeat cancer from the inside.
OxyLo develops enzyme-based microcapsule therapies delivered locally to solid tumors to improve efficacy while limiting off-target toxicity
We are innovation driven. Outcome Focused.
OxyLo develops enzyme-based microcapsule therapies that are delivered locally to solid tumors to improve efficacy while limiting off-target toxicity. Our platform is designed to solve a central challenge in oncology: how to concentrate therapeutic activity inside the tumor, not throughout the body.
This approach powers two programs: HypoxyCaps for metabolic tumor disruption and ProCaps for local prodrug activation.
For patients who are no longer eligible for surgery, every day matters.
The Solution
Our patented cutting edge microcapsule technology provides a large level of control using a small package.
Our Caps are Designed to be:
TUNABLE
Our synthesis method let’s us finely control the size and contents of hypoxyCaps.
BIODEGRABLE
Designed to degrade in weeks within the body
EASY TO DEPLOY
Can be swapped directly into existing practices.
PRECISELY ENGINEERED
Formulated with special enzymes that starve tumors of what they need to survive.
SHELF STABLE
Made to last for months in storage.
Robust Pipeline
We are advancing a robust and diverse pipeline of enzyme based microcapsules to potential expand the horizon of treatment possibilities beyond the limit of other modalities. We are leveraging the advantages of our encapsulation system to address unmet needs in across a range of solid tumor types, including hepatocellular carcinoma, pancreatic ductal adenocarcinoma, and more. Learn more about our pipeline.
